Lv4
630 积分 2020-04-15 加入
Emerging evidence for adapting radiotherapy to immunotherapy
8个月前
已完结
LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
11个月前
已关闭
Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer
1年前
已完结
Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non–Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies
1年前
已完结
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
1年前
已完结
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
2年前
已完结
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
2年前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
4年前
已完结
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China
4年前
已完结
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF -mutant metastatic colorectal cancer (SWOG 1406)
4年前
已关闭
皖公网安备34019202002308
